Literature DB >> 12136745

Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery.

R Ferriols-Lisart1, F Ferriols-Lisart, V Jiménez-Torres.   

Abstract

OBJECTIVE: To evaluate the effectiveness and safety of bemiparin in the prophylaxis of thromboembolism in orthopaedic surgery with respect to other low-molecular-weight heparins.
METHODS: A meta-analysis of effectiveness and safety of low-molecular weight heparins versus standard heparin in orthopaedic surgery was performed. A literature search was done of Medline and Excerpta Medica from 1988 to 1998. Only controlled clinical trials were selected for meta-analysis. Differences between groups were expressed as odds ratios and these were combined by the Mantel-Haenszel method. MAIN OUTCOME MEASURES: Rates of deep vein thrombosis, pulmonary embolism and wound haematoma.
RESULTS: Twenty-one studies involving 4605 patients were included in the meta-analysis. Bemiparin significantly reduces the rates of deep vein thrombosis (OR; 95% CI = 0.38, 0.15-0.90). No significant differences were found in pulmonary embolism and wound haematoma. The incidence of deep vein thrombosis is also lower with enoxaparin than with unfractionated heparin. However, only nadroparin reduced the incidence of pulmonary embolism (ORs = 0.24, 95% CI = 0.05-0.94). In any case, the incidence of wound haematoma was not significant.
CONCLUSION: Bemiparin seems to be as effective and safe as the other low-molecular-weight heparins in the prevention of thromboembolic complications in orthopaedic surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12136745     DOI: 10.1023/a:1016187426582

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  57 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers--a dose-finding study within the therapeutical range.

Authors:  L Falkon; M Bayés; G Frontera; M Garí; M Barbanoj; J Fontcuberta
Journal:  Thromb Haemost       Date:  1997-01       Impact factor: 5.249

Review 3.  Low-molecular-weight heparins.

Authors:  J I Weitz
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

4.  Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.

Authors:  B I Eriksson; P Kälebo; B A Anthymyr; H Wadenvik; L Tengborn; B Risberg
Journal:  J Bone Joint Surg Am       Date:  1991-04       Impact factor: 5.284

Review 5.  Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

Authors:  L N Jørgensen; P Wille-Jørgensen; O Hauch
Journal:  Br J Surg       Date:  1993-06       Impact factor: 6.939

6.  Comparison of antithrombotic efficacy and haemorrhagic side-effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery.

Authors:  A Planes
Journal:  Blood Coagul Fibrinolysis       Date:  1993-12       Impact factor: 1.276

7.  Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement.

Authors:  V Avikainen; H von Bonsdorff; E Partio; P Kaira; S Hakkinen; J P Usenius; R Kaaja
Journal:  Ann Chir Gynaecol       Date:  1995

8.  Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.

Authors:  D R Anderson; B J O'Brien; M N Levine; R Roberts; P S Wells; J Hirsh
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

9.  Prevention of deep vein thrombosis after major knee surgery--a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo.

Authors:  J R Leclerc; W H Geerts; L Desjardins; F Jobin; F Laroche; F Delorme; S Haviernick; S Atkinson; J Bourgouin
Journal:  Thromb Haemost       Date:  1992-04-02       Impact factor: 5.249

10.  Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.

Authors:  C W Colwell; T E Spiro; A A Trowbridge; B A Morris; H C Kwaan; J D Blaha; A J Comerota; V A Skoutakis
Journal:  J Bone Joint Surg Am       Date:  1994-01       Impact factor: 5.284

View more
  1 in total

Review 1.  Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.

Authors:  Therese M Chapman; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.